Company profile for Kura Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on the cancer’s genetic makeup. This new era of precision medicine offers the potential for innovative treatments that are safer and more effective for patients with certain can...
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on the cancer’s genetic makeup. This new era of precision medicine offers the potential for innovative treatments that are safer and more effective for patients with certain cancers. We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Kura Oncology, Inc. (Headquarters) 3033 Science Park Road, Suite 220 San Diego...
Telephone
Telephone
(858) 500-8800
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/03/3198898/35186/en/Kura-Oncology-to-Host-Virtual-Investor-Event-to-Discuss-Data-Presented-at-ASH-2025-on-Triplet-Combination-of-Ziftomenib-KOMZIFTI-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-.html

GLOBENEWSWIRE
03 Dec 2025

https://www.globenewswire.com/news-release/2025/11/25/3194795/35186/en/KOMZIFTI-ziftomenib-Added-to-National-Comprehensive-Cancer-Network-NCCN-Guidelines-for-Acute-Myeloid-Leukemia-AML.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3189595/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-Komzifti-ziftomenib.html

GLOBENEWSWIRE
17 Nov 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220305

FDA
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/13/3187609/35186/en/Kura-Oncology-and-Kyowa-Kirin-Announce-FDA-Approval-of-KOMZIFTI-ziftomenib-the-First-and-Only-Once-Daily-Targeted-Therapy-for-Adults-with-Relapsed-or-Refractory-NPM1-Mutated-Acute-.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186755/35186/en/Kura-Oncology-to-Participate-in-Upcoming-Investor-Conference.html

GLOBENEWSWIRE
12 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty